Zilovertamab (formerly known as cirmtuzumab or UC‐961) is a monoclonal antibody to ROR1 and is in clinical trials for the treatment of leukaemias and other cancers, such as prostate cancer and lung cancer.42, 43. The gene discussed is ROR1; the disease is leukemia.